Stentys Enrolls First Heart Attack Patient in Pivotal U.S. Clinical Trial
5/20/2013 10:04:53 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
PRINCETON, N.J. & PARIS--(BUSINESS WIRE)--STENTYS (FR0010949404 – STNT), a medical technology company commercializing in Europe the world's first and only Self-Apposing® Stent to treat acute myocardial infarction (AMI), announced today that the first patient was enrolled in APPOSITION V, the pivotal FDA-approved IDE trial which will enable the Company to apply for marketing approval of the Self-Apposing Stent in the United States.
Help employers find you! Check out all the jobs and post your resume.
comments powered by